atazanavir sulfate has been researched along with dolutegravir in 19 studies
| Studies (atazanavir sulfate) | Trials (atazanavir sulfate) | Recent Studies (post-2010) (atazanavir sulfate) | Studies (dolutegravir) | Trials (dolutegravir) | Recent Studies (post-2010) (dolutegravir) |
|---|---|---|---|---|---|
| 1,102 | 246 | 590 | 1,128 | 179 | 1,105 |
| Protein | Taxonomy | atazanavir sulfate (IC50) | dolutegravir (IC50) |
|---|---|---|---|
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Chain A, PFV integrase | Human spumaretrovirus | 0.0517 | |
| Solute carrier family 22 member 2 | Homo sapiens (human) | 1.9 | |
| Integrase | Human immunodeficiency virus 1 | 0.0414 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Borland, J; Chen, S; Lou, Y; Min, S; Peppercorn, A; Piscitelli, SC; Song, I; Wajima, T | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S; Rigo, F; Vento, S | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Alnouti, Y; Bade, AN; Dash, PK; Edagwa, B; Gautam, N; Gelbard, HA; Gendelman, HE; Gnanadhas, DP; Gorantla, S; Lin, Z; McMillan, J; Mosley, RL; Palandri, DL; Sillman, B | 1 |
| Ancona, G; Cannizzo, ES; Castagna, A; Galli, A; Galli, L; Gianotti, N; Marchetti, G; Merlini, E; Monforte, AD; Muccini, C; Tincati, C | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bonora, S; Carosella, S; Castagna, A; Cattelan, A; De Socio, GV; Di Giambenedetto, S; Galli, L; Gulminetti, R; Ladisa, N; Mazzola, G; Mena, M; Poli, A; Quiros-Roldan, ME; Riva, A; Rusconi, S | 1 |
| Biasiotto, G; Bonito, A; Calza, S; Castelli, F; Quiros-Roldan, E; Vezzoli, M; Zanella, I | 1 |
| Cenderello, G; Di Biagio, A; Magnasco, L; Rizzardini, G | 1 |
| Castagna, A | 1 |
| Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V | 1 |
| Cassola, G; Del Puente, F; Pontali, E; Torresin, A | 1 |
| Auclair, M; Capeau, J; Fellahi, S; Garcia, M; Guénantin, AC | 1 |
| Cazzaniga, A; Galli, M; Maier, J; Rusconi, S; Scrimieri, R | 1 |
| Alimohamadi, Y; Fard, SR; Kalantari, S; Maleki, D; Minaeian, S; Taher, MT; Yassin, Z | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
1 review(s) available for atazanavir sulfate and dolutegravir
| Article | Year |
|---|---|
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
3 trial(s) available for atazanavir sulfate and dolutegravir
| Article | Year |
|---|---|
Effect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Linear Models; Male; Middle Aged; Oligopeptides; Oxazines; Piperazines; Pyridines; Pyridones; Ritonavir; Young Adult | 2011 |
Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients.
Topics: Antiviral Agents; Atazanavir Sulfate; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Hydroxychloroquine; Lopinavir; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Treatment Outcome | 2021 |
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
15 other study(ies) available for atazanavir sulfate and dolutegravir
| Article | Year |
|---|---|
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Female; Heterocyclic Compounds, 3-Ring; HIV-1; Humans; Macrophages; Male; Mice; Nanoparticles; Oxazines; Piperazines; Pyridines; Pyridones; Pyrroles | 2017 |
Immune activation, inflammation and HIV DNA after 96 weeks of ATV/r monotherapy: a MODAt substudy.
Topics: Adult; Atazanavir Sulfate; DNA; Heterocyclic Compounds, 3-Ring; HIV; Humans; Inflammation; Oxazines; Piperazines; Pyridones | 2018 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Substitution; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2019 |
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytokines; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Inflammation; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2020 |
Response to letter to the editor: switch to dolutegravir and unboosted atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.
Topics: Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Atazanavir Sulfate; Carbamazepine; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Oxcarbazepine; Piperazines; Pyridones | 2020 |
Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.
Topics: Adult; Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Comorbidity; Coronary Vessels; Endothelial Cells; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; NF-kappa B; Oxazines; Piperazines; Pyridones; Ritonavir; Signal Transduction; Sirtuin 1; Ubiquitin Thiolesterase | 2020 |
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Osteogenesis; Oxazines; Piperazines; Pyridones | 2021 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |